Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|
HR | 95% CI | P-value | Coefficient | HR | 95% CI | P-value | |
Model group (n = 348) | |||||||
Age (high/low) | 1.254 | 0.887–1.772 | 0.199 | 0.204 | 1.227 | 0.838–1.797 | 0.294 |
Gender (male/female) | 0.817 | 0.573–1.164 | 0.264 | − 0.123 | 0.884 | 0.602–1.298 | 0.530 |
AJCC PT (T4, T3/T2, T1) | 2.548 | 1.794–3.617 | < 0.001 | 0.614 | 1.847 | 0.244–13.991 | 0.553 |
AJCC PN (N2, N1/N0) | 1.509 | 1.048–2.174 | 0.027 | − 0.132 | 0.876 | 0.542–1.417 | 0.590 |
AJCC PM (MX, M1/M0) | 1.674 | 1.162–2.413 | 0.006 | 0.622 | 1.863 | 1.159–2.993 | 0.010 |
AJCC stage (IV, III/II, I) | 2.442 | 1.685–3.540 | < 0.001 | 0.169 | 1.184 | 0.158–8.868 | 0.870 |
LncRNA risk prediction score (high/low) | 4.140 | 2.801–6.120 | < 0.001 | 1.421 | 4.141 | 2.705–6.340 | < 0.001 |
Validation cohort (n = 348) | |||||||
Age (year) | 2.057 | 1.421–2.978 | < 0.001 | 0.528 | 1.696 | 1.129–2.550 | 0.011 |
Gender (male/female) | 0.777 | 0.542–1.113 | 0.169 | − 0.062 | 0.940 | 0.629–1.403 | 0.761 |
AJCC PT (T4, T3/T2, T1) | 1.890 | 1.294–2.762 | 0.001 | 0.433 | 1.541 | 0.201–11.816 | 0.677 |
AJCC PN (N2, N1/N0) | 1.635 | 1.143–2.339 | 0.007 | − 0.084 | 0.919 | 0.585–1.443 | 0.714 |
AJCC PM (MX, M1/M0) | 1.681 | 1.171–2.413 | 0.005 | 0.392 | 1.480 | 0.940–2.330 | 0.091 |
AJCC stage (IV, III/II, I) | 1.687 | 1.123–2.534 | 0.012 | − 0.005 | 0.995 | 0.134–7.405 | 0.996 |
LncRNA risk prediction score (high/low) | 3.891 | 2.615–5.788 | < 0.001 | 1.292 | 3.639 | 2.345–5.645 | < 0.001 |